Author:
McGuire William,Fowlie Peter W.
Abstract
Abstract
The TIPP investigators assessed whether prophylactic indomethacin, used to reduce the incidence of PDA and severe IVH, reduced the risk of death or adverse neurodevelopmental outcomes in extremely low birth weight infants. This multicenter trial assigned 1202 infants, soon after birth, to receive indomethacin (0.1 mg/kg) or placebo intravenously once daily for 3 days. The primary outcome was a composite of death, cerebral palsy, cognitive delay, deafness, or blindness at 18 months’ post-term. This composite outcome was found to be similar in the intervention and placebo cohorts (47% versus 46%, respectively; odds ratio [OR] 1.1, 95% CI 0.8 to 1.4). Severe periventricular hemorrhage, but not other intracranial abnormalities seen on cerebral ultrasound, was lower in the indomethacin group (9% versus 13%; OR 0.6, 95% CI 0.4 to 0.9, p = 0.02).
Publisher
Oxford University PressNew York
Reference8 articles.
1. Long-term effects of indomethacin prophylaxis in extremely low birth weight infants.;N Engl J Med,2001
2. Predictive value of the Bayley scales of infant development on development of very preterm/very low birth weight children: a meta-analysis.;Early Hum Dev,2013
3. Retrospective economic evaluation of a controlled trial of indomethacin prophylaxis for patent ductus arteriosus in premature infants.;Early Hum Dev,2006
4. A prospective study of maternal preference for indomethacin prophylaxis versus symptomatic treatment of a patent ductus arteriosus in preterm infants.;BMC Pediatr,2015
5. 2395. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010;2010(7):CD000174.